K-ras mutations in the plasma correspond to computed tomographic findings in patients with pancreatic cancer

Pancreas

Volumn 41, Issue 2, 2012, Pages 323-325

  Däbritz, Jan ^a,b   Preston, Roman ^a,c   Hänfler, Joachim ^a   Oettle, Helmut ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; DNA; K RAS PROTEIN; PEPTIDE NUCLEIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DISEASE ASSOCIATION; DISEASE MARKER; GENE FREQUENCY; GENE MUTATION; HUMAN; LETTER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; DNA MUTATIONAL ANALYSIS; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84857917306     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182289118     Document Type: Letter

References (7)

1. Wu X, Lu XH, Xu T. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Clin J Dig Dis. 2006;7:170-174. (Pubitemid 43983749)
2. Chen H, Tu H, Meng ZQ, et al. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol. 2010;36(7):657-662.
3. Olsen CC, Schefter TE, Chen H, et al. Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy. Am J Clin Oncol. 2009;32(2): 115-121.
4. Castells A, Puig P, Móra J, et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol. 1999;17(2):578-584. (Pubitemid 29075245)
5. Däbritz J, Preston R, Hänfler J, et al. Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9. Pancreas. 2009;38(5):534-541.
6. Preston R, Däbritz J, Hänfler J, et al. Mutational analysis of K-ras codon 12 in blood samples of patients with acute myeloid leukemia. Leuk Res. 2010;34(7): 883-891.
7. Däbritz J, Hänfler J, Preston R, et al. Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes. Br J Cancer. 2005;92(2):405-412. (Pubitemid 40343159)